Insmed Unusual Options Activity For July 11

Investors with a lot of money to spend have taken a bearish stance on Insmed INSM.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with INSM, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 14 uncommon options trades for Insmed.

This isn't normal.

The overall sentiment of these big-money traders is split between 21% bullish and 57%, bearish.

Out of all of the special options we uncovered, 3 are puts, for a total amount of $120,150, and 11 are calls, for a total amount of $1,054,930.

Predicted Price Range

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $75.0 for Insmed over the recent three months.

Insights into Volume & Open Interest

In terms of liquidity and interest, the mean open interest for Insmed options trades today is 3346.29 with a total volume of 975.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Insmed's big money trades within a strike price range of $30.0 to $75.0 over the last 30 days.

Insmed Call and Put Volume: 30-Day Overview

Biggest Options Spotted:

About Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

In light of the recent options history for Insmed, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Insmed's Current Market Status

• Currently trading with a volume of 1,989,221, the INSM's price is up by 3.65%, now at $75.77.
• RSI readings suggest the stock is currently may be overbought.
• Anticipated earnings release is in 21 days.

What The Experts Say On Insmed

In the last month, 5 experts released ratings on this stock with an average target price of $86.6.

• Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Insmed with a target price of $83.
• An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Insmed, which currently sits at a price target of $75.
• Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Insmed, targeting a price of $102.
• Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Insmed, targeting a price of $83.
• Consistent in their evaluation, an analyst from HC Wainwright & Co. keeps a Buy rating on Insmed with a target price of $90.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Insmed, Benzinga Pro gives you real-time options trades alerts.